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Abstract
Background: CD10 is a transmembrane metallo-endopeptidase that cleaves and inactivates a
variety of peptide growth factors. Loss of CD10 expression is a common, early event in human
prostate cancer; however, CD10 positive cancer cells frequently appear in lymph node metastasis.
We hypothesize that prostate tumors expressing high levels of CD10 have a more aggressive
biology with an early propensity towards lymph node metastasis.
Methods: Eighty-seven patients, 53 with and 34 without pathologically organ confined prostate
cancer at the time of radical prostatectomy (RP), were used for the study. Fourteen patients with
lymph node metastasis found at the time of surgery were identified and included in this study. Serial
sections from available frozen tumor specimens in OCT were processed for CD10
immunohistochemistry. Cancer glands were graded for the presence and intensity of CD10
staining, and overall percentage of glands staining positive was estimated. Clinical characteristics
including pre- and post-operative PSA and Gleason score were obtained. A similar study as a
control for the statistical analysis was performed with CD13 staining. For statistical analysis, strong
staining was defined as > 20% positivity based on the observed maximum separation of the
cumulative distributions.
Results: CD10 expression significantly correlated with Gleason grade, tumor stage, and with pre-
operative serum PSA. Seventy percent of RP specimens from patients with node metastasis showed
strong staining for CD10, compared to 30% in the entire cohort (OR = 3.4, 95% CI: 1.08–10.75, P
= 0.019). Increased staining for CD10 was associated with PSA recurrence after RP. CD13 staining
did not correlate significantly with any of these same clinical parameters.
Conclusion: These results suggest that the expression of CD10 by prostate cancer corresponds
to a more aggressive phenotype with a higher malignant potential, described histologically by the
Gleason score. CD10 offers potential clinical utility for stratifying prostate cancer to predict
biological behavior of the tumor.
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The cluster designation (CD) antigens are cell surface
molecules first defined on human leukocytes and later
found to be expressed by a variety of human cell types in
both normal and pathologic states. The human prostate
has been CD immunophenotyped and differences in the
expression of several CD molecules were seen between
cancer and normal prostate tissue [1]. Among these is the
common acute lymphocytic leukemia antigen (CALLA)
CD10. CD10 is a 100-kDa transmembrane glycoprotein,
also known as neutral endopeptidase (NEP), membrane
metallo-endopeptidase (MME), or enkephalinase,
involved in the cleavage and inactivation of certain pep-
tide hormones important for signal transduction includ-
ing the enkephalins, bombesin, and substance P. The
biological function of these potential CD10 substrates in
the prostate is unknown. Prostate stromal fibromuscular
cells, however, express proenkephalin, which may be a
substrate for CD10 within the prostate [2]. CD10 is
strongly expressed by normal prostatic luminal epithelial
cells and is a normal component of human prostasomes
[3].
Loss of CD10 expression by metastatic prostate cancer was
first reported to contribute to androgen independent
tumor growth [4]. In addition to prostate cancer, CD10
expression has been examined in other epithelial cancers
including kidney, breast, lung, and skin. CD10 expression
is greater in more advanced primary melanomas and is
upregulated in metastatic lesions compared with the cor-
responding primary tumors [5,6]. Normal tissue and well
differentiated tumors of the colon and stomach express
CD10 while poorly differentiated tumors from these sites
show decreased expression [7]. Lung and kidney tumors
show a similar pattern of decreased expression compared
to the normal parenchyma [8], while hepatocellular and
thyroid carcinoma express high levels [9,10]. It may be
gathered that CD10 function likely varies by tissue type
and disease state.
A high percentage of prostate tumors show an early loss of
CD10 expression [1,11]. Tawfic et al. [12] reported an
absence of CD10 expression by Gleason grade 2 and 3
tumors however noted high expression of cytoplasmic
and membranous CD10 in high Gleason tumors. High
Gleason grade has been well established as a marker of
aggressive biological behavior and is one of the best pre-
dictors of patient outcome from prostate cancer that we
have available today. While primary tumors show a range
of CD10 expression, lymph node metastases show nearly
uniform high levels of expression [1]. We postulate that
prostate tumors expressing high levels of CD10 correlate
with a poor disease outcome. Less than 5% of patients are
found to have lymph node metastasis at the time of radi-
cal prostatectomy (RP) for clinically localized prostate
cancer, but up to 30% of patients will experience bio-
chemical failure (rising PSA) or gross disease recurrence
after surgery. These findings may be due to significant
clinical under-staging and suggests that many sub-clinical
metastases are not diagnosed at the time of surgery for
presumed localized disease. Improved prediction of bio-
logically aggressive tumors with a high propensity
towards early metastasis would allow for either more
aggressive or more appropriate primary treatment. We
describe here our finding that CD10-positive tumors are
of a more aggressive cancer type predictive of lymph node
metastasis and biochemical recurrence after primary ther-
apy. Osman et al. [13] have earlier reported a study on
prostate cancer CD10 expression. Although our immuno-
histochemistry data are similar in that a majority of
tumors are CD10-negative and CD10+ cancer cells tend to
be found in higher Gleason grades, our findings regarding
PSA recurrence after RP are at odds. We will discuss possi-
ble explanations for our disparate findings in this paper as
well.
Methods
1. CD immunohistochemistry
This study was carried out under approval by the Univer-
sity of Washington IRB for the research use of excess tissue
from surgeries. Frozen blocks of tumor tissue in OCT were
retrieved from the tumor bank in the Department of Urol-
ogy, and multiple 5-μm serial sections were cut from each
specimen and fixed in cold acetone for CD10 immunohis-
tochemistry. Details of this procedure have been previ-
ously described [1]. Each specimen was assigned a
numeric code with a letter code indicating the site origin
of the block (right apex, left mid, etc.). Cancer glands were
scored for the presence of CD10 staining, and overall per-
centage of glands staining positive in the different
Gleason component patterns was scored by a single
pathologist (LDT). Since benign glands stain positive for
CD10, this provided a reliable gauge for positive cancer
staining. An isotype control was also done as described
[1]. Eighty-seven patients, 53 with and 34 without patho-
logically organ-confined prostate cancer at the time of RP
were identified. The CD10 results of these specimens were
reported in ref. 1, and a formal statistical analysis relating
CD10 staining and clinicopathological characteristics is
presented here. In scoring, each tumor in the particular
section examined was characterized as containing what
percentage (0 to 100%) of Gleason pattern 3, pattern 4 or
pattern 5; then within each pattern, the percent positive
for CD10 staining. Fourteen patients with lymph node
metastasis found at the time of RP were identified and
included in this study. Clinical characteristics were
obtained from the medical records.
To further test our methods for estimating percent CD10
staining by specific Gleason pattern for correlation withPage 2 of 11
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analysis with a separate CD antigen. Another cohort of 66
patients was scored for CD13 immunohistochemistry and
subjected to the same statistical analysis described below.
The cancer glands were similarly characterized, and corre-
lation between staining and the same disease parameters
was investigated. CD13 was chosen, because it, like CD10,
is a cell surface peptide-processing enzyme (ANPEP, ami-
nopeptidase N) expressed by luminal cells, and a majority
of cancer glands were also found not to express CD13.
Like CD10, a smaller percentage of cancer glands were
positive for CD13. The CD13 cohort was not identical to
the CD10 cohort, but there was some overlap of subjects.
Because of the limited number of lymph node metastases
in our collection, the same node specimens were serially
stained for CD10 and CD13. Monoclonal CD10 (clone
HI10a) and CD13 (clone WM15) antibodies were
obtained from BD PharMingen (San Diego, CA). In our
hands, these antibodies worked well for frozen sections
[1]. Antibodies were used at a concentration of 4 ng/μl.
Immunolocalization was done by an indirect avidin-
biotin-peroxidase method as described previously [1]. In
both these investigations, tissue microarray was not used
because of inherent sampling problems with such arrays
as only a small portion of any tumor is represented. This
would make correlation with clinical outcome difficult as
we previously pointed out [1]. While the sections used
here were more representative, cancer foci in areas not
captured by the sections were nevertheless missed.
2. Statistical analysis
Standard statistical summaries and procedures were used
for visualization and significance testing of associations
with CD10, and with CD13, including scatterplots with
Pearson product-moment and Spearman nonparametric
correlation measures and tests, cumulative distribution
functions with Kolmogorov-Smirnov and Wilcoxon non-
parametric tests, and 1-way ANOVA. Nonparametric
methods were included due to non-normal distributions
and the presence of ordinal variables. For calculation of
odds ratios for lymph node metastasis and for estimating
PSA free survival, strong staining was defined as > 20%
positivity based on the observed maximum separation of
the cumulative distributions. PSA free survival was calcu-
lated using the Kaplan-Meier method and survival curves
were compared using the log-rank test. Only patients with
pathologically localized (pT2-T3N0) disease with an
undetectable PSA after RP were included in the survival
analysis. Patients with lymph node positive disease and
patients who received adjuvant therapy were excluded.
PSA recurrence was defined as any value ≥ 0.2 ng/ml after
an undetectable PSA after RP.
3. Gene expression analysis
DNA array analysis of cancer cell lines [14] and sorted
prostate cell populations [15] was done with Affymetrix
HG-U133 GeneChips. CD26 was used to sort luminal
cells, CD104 to sort basal cells, and CD49a to sort stromal
fibromuscular cells. In cell sorting, prostatectomy tissue
samples free of cancer were digested with collagenase and
the resultant cells were partitioned on Percoll density gra-
dients into epithelial and stromal fractions. Magnetic cell
sorting (MACS) was used to select the targeted cell popu-
lations after labeling with CD antibodies conjugated to R-
phycoerythrin (PE). The array datasets were comprised of
2 replicates for the cell lines and 5 replicates for the sorted
cells. In addition to the cell types mentioned, datasets
were obtained for benign tissue (NP), tumor tissue (CaP),
sorted cancer cells from a primary tumor (CD26+ CaP),
sorted endothelial cells (CD31) [15], putative epithelial
stem cells (CDw338/antibody clone 5D3). A description
of the sorted cancer cells and 5D3 cells will be reported
elsewhere. Data analysis was done with GeneSpring soft-
ware.
Results
1. Expression pattern of transmembrane peptidases in 
prostate cancer
Both CD10 and CD13 are expressed by luminal cells of
the prostatic epithelium but their expression in cancer is
heterogeneous [1]. Examples of all four possible CD10/
CD13 cancer cell types – CD10-/CD13-, CD10-/CD13+,
CD10+/CD13-, CD10+/CD13+ – were detected in our
cohort. Normal epithelium present in the specimens
showed the characteristic strong CD10 and CD13 expres-
sion at the luminal plasma membrane. Fig. 1 shows fro-
zen section examples of tumors stained serially for CD10
and CD13. In all three cases, the cancer glands were
mostly negative for CD10. In two cases, the cancer glands
were positive for CD13, and a small subpopulation of
CD13+ tumor cells was present in one case. These exam-
ples showed that CD13+ cancer cells could be found in
tumors with either a glandular (Gleason 3) or non-glan-
dular (Gleason 4) morphology. Overall, the predominant
cancer cell phenotype was CD10-/CD13-, and this was val-
idated by DNA array analysis data shown in Fig. 2. As can
be seen, the expression pattern was similar for CD13 and
CD10 (except in the cancer cell lines) with both CD10
and CD13 expression down-regulated in cancer speci-
mens. For the cell lines, the expression profiles of these
two genes were in agreement with the reported flow
cytometry and immunocytochemistry data [11,16]. The
data also showed that expression of any particular gene
was variable in cancer; one cancer cell type may express it
while another one may not. Their differential expression
in cell lines may reflect the situation in tumors, where
either positive or negative cancer cell types are found.Page 3 of 11
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stage
In the CD10 cohort, a trend was seen that in tumors with
predominantly pattern 3 cancer (Gleason score 3+3 = 6)
the percentage of positive CD10 staining was less than 5–
10%. Higher percentages were found in tumors with pat-
terns 4 or 5, although some pattern 3 tumors were also
positive [1]. Correlations between CD10 percentage and
Gleason score, clinical stage and pre-operative serum PSA
level are summarized in Table 1 and are as follows. The
first scatter plot (Fig. 3) shows the relationship between
percent positive and Gleason score with jitter added to
allow separation of multiple observations with identical
data values for viewing purposes. The result was pooled
based on relative similarity at advanced grades, combin-
ing all cases more advanced than 3+3 into a single group
(n = 69) and compared to that of 3+3 (n = 18). Clinically,
there is a clear behavioral difference between Gleason pat-
tern 3 and pattern 4/5 tumors. The result, shown as cumu-
lative distributions, was very highly statistically significant
(Wilcoxon Z = 3.645, P = 0.0003; Kolmogorov-Smirnov D
= 0.551, P = 0.0003) with higher percent positive associ-
ated with advanced Gleason scores. The mean increased
from 4.1% to 32%, while the median increased from 2%
to 20% for Gleason score 6 and Gleason score 7, 8 and 9
tumors, respectively. The maximum separation of the
cumulative distributions, 100%-44.9%, occurred at 15%
positive. The result was significant across all Gleason
scores (1-way ANOVA F = 4.214 with 3 and 83 degrees of
freedom, P = 0.00796). The Spearman correlation was ρ =
0.336, P = 0.00148 with n = 87. The second scatter plot
(fig. 4) shows the relationship between percent positive
and stage. The result was pooled based on the relative
sparseness at advanced stages (combining stages T3 and
T4), and was separated to compare organ confined (T2N-
, n = 49) to non-organ confined stages (T2N+, T3, T4, n =
38) as shown in the cumulative distributions. The differ-
ences were statistically significant (Wilcoxon Z = 2.316, P
= 0.0206; Kolmogorov-Smirnov D = 0.320, P = 0.0253;
Spearman ρ = 0.234, P = 0.0293 with n = 87), with more
advanced stages having significantly higher percent posi-
tive staining. The mean increased from 20.6% to 33.5%,
while the median increased from 5% to 23.4% for the
organ confined and non-organ confined stages, respec-
tively. The maximum separation of the cumulative distri-
butions, 71.4%-39.5%, occurred at 17% positive. The
third scatter plot (Fig. 5) shows the relationship between
percent positive and pre-operative PSA level (logarithmic
scale, n = 84 observations after 3 were omitted due to
missing values). There was a statistically significant rela-
CD10 and CD13 prostate cancer cell typesFigure 1
CD10 and CD13 prostate cancer cell types. Positive staining is indicated by the brown chromogen deposit. Non-cancer 
glands are generally positive for both CD10 and CD13. In the left and middle cases the tumors consist of small crowded glands 
in the left half of the field. Most of the cancer glands are CD10- and CD13+, although a few isolated CD10+ cancer glands can be 
seen. In the right case, a subpopulation of CD13+ cancer cells are present in the larger population of CD10-/CD13- cancer cells. 
This tumor shows no glandular morphology. Magnification is 20×.Page 4 of 11
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higher percent positive associated with higher PSA levels.
The relationship and its significance were robust to the 3
possible outliers with the highest PSA levels (correlation
of 0.241, P = 0.0299, when these were omitted). The
Spearman correlations were ρ = 0.300, P = 0.00555 with n
= 84, and ρ = 0.279, P = 0.0118 with n = 81 minus the 3
outliers.
The second analysis showed no statistically significant
correlations between CD13 and the same pathologic and
clinical parameters. A scatter plot (Fig. 6) shows the rela-
tionship between percent positive and Gleason score. The
result was analyzed by combining all cases that were more
advanced than 3+3 into a single group (n = 54) and com-
pared to that of 3+3 (n = 12). The resulting cumulative
distributions showed that the relationship was not statis-
tically significant (Wilcoxon Z = 1.439, P = 0.075; Kol-
mogorov-Smirnov D = 0.296, P = 0.355; Spearman ρ =
0.0700, P = 0.576 with n = 66). The next scatter plot shows
the relationship between percent positive and stage. When
the result was separated to compare T2N- (n = 39) to the
more advanced stages (n = 27), as shown in the cumula-
tive distributions, the differences were again not statisti-
cally significant (Wilcoxon Z = 0.548, P = 0.584;
Kolmogorov-Smirnov D = 0.214, P = 0.460; Spearman ρ =
-0.111, P = 0.375 with n = 66).
3. CD10 and lymph node involvement
Nearly all lymph node metastases available in our collec-
tion (8/9) displayed strong staining for CD10 (Fig. 7).
Seventy percent of RP specimens from patients with node
metastasis showed strong staining (> 20%) for CD10,
compared to 30% in the entire cohort (OR = 3.4, 95% CI:
1.08–10.75, P = 0.019). Thus, patients with tumors stain-
ing heavily for CD10 were more likely to harbor lymph
node metastasis at the time of RP. Tumor cell lines derived
from node metastases, LNCaP, C4-2 (Fig. 2) and xenograft
LuCaP 35 [16], are CD10+.
4. CD10 and PSA recurrence
Thirteen patients in our cohort with a mean follow-up of
29 months experienced PSA recurrence after treatment
while 32 remained disease free. Figure 8 depicts the Kap-
lan-Meier PSA free survival stratified by percent positive
staining for CD10. Patients with > 20% staining for CD10
showed significantly worse PSA free survival after RP (P =
0.03).
Discussion
Prostate cancer is a heterogeneous disease with different
clinical presentations, responses to therapy, and long-
term outcomes. One of the more difficult challenges in
treating this disease involves identifying and distinguish-
ing aggressive tumors from those likely to remain indo-
lent with little detriment to the patient. Recent advances
in high-throughput genomic and proteomic analysis of
prostate cancer have begun to describe the biological dif-
ferences of these tumor types at the molecular level. Pros-
tate cancer primary tumors show heterogeneous
expression of CD10 with early loss of expression by many
tumors [11]. Most lymph node metastases, however,
strongly express the antigen suggesting that CD10 expres-
sion may be a marker for or involved in the pathogenesis
Gene expression profilesFigur  2
Gene expression profiles. Expression for CD10 and CD13 is quantified by DNA array signals on the y-axis (in log scale). 
Most of the published raw data are available from our website. On the x-axis are listed the biospecimens analyzed: NP, CaP tis-
sue; sorted cancer, luminal, basal, stromal, endothelial and 5D3 cells; LNCaP, C4-2, PC3 and CL1 prostate cancer cell lines. 
The expression levels of these genes in the cancer cell lines are in agreement with other experimental results. Note the 
decrease in CD10 and CD13 between sorted CD26+ cancer cells and normal luminal cells. This is also evident in the NP vs. 
CaP comparison.Page 5 of 11
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Percent CD10 positive and Gleason scoreFigure 3
Percent CD10 positive and Gleason score. Shown are the scatterplot (top) and cumulative distributions (bottom) of per-
centage of tumor CD10 positivity and Gleason score. Differences in CD10 cancer expression are significant when Gleason 
scores are sorted into 3+3 and > 3+3.
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Percent CD10 positive and stageFigure 4
Percent CD10 positive and stage. Shown are the scatterplot (left) and cumulative distributions (bottom) of percentage of 
tumor CD10 positivity and clinical stage. Differences in CD10 expression are significant when stages are sorted into T2N- and 
T2N+/T3/T4.
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CD10 expression correlated with advanced Gleason score,
and thus with more aggressive tumors with poor patho-
logical and biochemical outcomes. We found that
patients with primary tumors expressing high levels of
CD10 were more likely to harbor lymph node metastasis
and experience PSA recurrence after RP. Comparative
array analysis among Gleason pattern 3, pattern 4 and pat-
tern 5 tumors microdissected by laser-capture showed
increased CD10 expression in the higher patterns [17]; a
trend also reported by the study of Osman et al. [13].
In contrast to our results, Osman et al. propose that loss
of CD10 expression is associated with an unfavorable
patient outcome. This group found that complete loss of
CD10 expression was associated with PSA recurrence after
RP. Since a majority of tumors are CD10-negative (found
in both of our cohorts), their conclusion would suggest a
higher failure rate than is observed clinically, and would
contradict the well established risk for disease recurrence
by Gleason score (lower Gleason score tumors tend to be
CD10-negative). Our analysis was different and showed
decreased PSA free survival after RP for men with high
staining for CD10 in their primary tumor. CD10 expres-
sion patterns in the Osman study were not reported by
specific Gleason pattern within individual tumors which
makes our studies difficult to compare. This study also
found a significant association between heterogeneous
expression of CD10 and African American race. The
majority of cases in the Osman study were African Ameri-
can while our cohort consisted primarily of Caucasian
men.
Sampling variations may account for some of the
observed differences between our studies. Statistical anal-
ysis for correlation of markers with disease outcome is
affected by sampling as a tissue section for immunohisto-
chemistry only captures a portion of the tumor in the
prostate (see the tumor CD13 heterogeneity in Fig. 1).
This is more pronounced when using tissue microarrays
[11], unless individual Gleason components of every case
are systematically arrayed (which is not usually done).
With our methods, each tumor was analyzed with respect
to CD10 staining by the individual component Gleason
patterns. We did not observe an absolute trend in staining
with all pattern 3 s negative and all patterns 4 s and 5 s
positive [1]. Such heterogeneity may make correlations
between marker and outcome difficult if not taken into
account. We performed a second analysis with another
Percent CD10 positive and pre-operative PSAFigure 5
Percent CD10 positive and pre-operative PSA. The scatterplot shows the relationship between the percentage of CD10 
positivity and serum PSA level before surgery.Page 8 of 11
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Significantly, prostate tumors showed similar heterogene-
ity in CD10 and CD13 staining but we found no correla-
tion between CD13 staining and clinical parameters.
More importantly, there was no increase in CD13 reactiv-
ity in the node metastasis specimens. In biomarker analy-
sis, we think it is crucial to analyze expression of
candidates (especially those that show differential expres-
sion in tumors) in both primary cancer and node metas-
tasis. In contrast to other studies, our analysis was
performed on frozen tissue specimens. We have per-
formed IHC for CD10 on adjacent formalin fixed paraffin
embedded tissues and have observed similar results.
Albrecht et al. [19] have reported a shift from membrane
bound to cytoplasmic localization for CD10 in high-grade
prostate cancer cells with a loss of CD10 expression in
areas of high proliferative activity as indicated by Ki67
immunohistochemistry (n = 24, with perhaps around 7
containing CD10+ cancer cells based on their frequency).
It is unclear, however, if individual CD10+ vs. CD10- can-
cer cells were scored for Ki67 (by double labeling for
example), and there was no statistical analysis of their
data. Given the generally low Ki67 reactivity in prostate
cancer [20] we are not sure how to interpret these data
regarding lower CD10 expression in areas of apparent
high proliferative activity. Furthermore, the authors report
no Ki67 staining for lymph node metastases where a
majority of cancer cells are CD10-positive.
While cancer cells in lymph nodes were found to be
CD10-positive (though not all), cancer cells in other
metastases were not (unpublished data). Both LNCaP and
LuCaP 35, derived from lymph node metastases, are
Table 1: Correlation between clinicopathologic characteristics and increased percent positive staining for CD10.
n Spearman Coefficient P value
Increasing Pre-treatment PSA 81 0.3 0.006
Stage ≥ pT3 38 0.234 0.03
Gleason ≥ 7 69 0.336 0.001
Statistical analysis of CD13 positivity and disease characteristicsFigure 6
Statistical analysis of CD13 positivity and disease characteristics. Shown are the scatter plot (left top) and cumulative 
distributions (left bottom) of percent CD13 positive and Gleason score, and also those (right top and bottom respectively) for 
percent positive and stage; differences are not statistically significant.Page 9 of 11
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CL1, are CD13+ [11] (Fig. 2). The presence of CD13 in
PC3 (established from a bone metastasis) and CL1 (which
can metastasize to multiple organs) cell lines might indi-
cate its role in metastasis to other organ sites given that
CD13 has been shown to function in metastasis [21,22].
It is possible then that the function of CD10 is employed
primarily in cancer spread to lymph nodes. A molecular
explanation for the functioning of CD10, since both nor-
mal luminal cells and cancer cells express it, may come
from our recent analysis that showed association of CD10
with Hsp27 (and others) in C4-2 and LNCaP cells [23].
This association is cancer-specific as CD10 and Hsp27 are
expressed by different cell types in benign tissue (CD10 by
luminal and Hsp27 by basal). Whether this association is
also found in the CD10-positive tumors is difficult to
answer because the technique at present is not adequate
for the generally small amounts of available clinical mate-
rial. Prostate cancer expression of Hsp27 has been linked
to poor outcome by Cornford et al. [24] and therefore,
cancer expression of either CD10 or Hsp27 appears to be
both associated with a poor prognosis.
If our current findings are verified with another larger
cohort with long-term follow-up, CD10 might offer a
potential clinical utility for stratifying prostate cancer in
an attempt to predict biological behavior of the tumor. An
immunohistochemistry-based test can be used in the clin-
ical setting to identify CD10-positive tumors on prostate
needle biopsies, which may warrant more aggressive ini-
tial therapy or closer surveillance post-operatively. A
number of drugs against CD10 are available and potential
targeted therapies could be formulated based on these
drugs, including monoclonal antibody mediated-delivery
of chemotherapy.
Conclusion
CD10 expression by prostate cancer correlates with
Gleason score and other clinical predictors of aggressive
disease, notably nodal involvement. The role of CD10 in
the pathobiology of early, hormone sensitive prostate
cancer remains to be determined.
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Percent CD10 positive and PSA recurrenceFigure 8
Percent CD10 positive and PSA recurrence. Kaplan-
Meier analysis shows significantly lower PSA free survival for 
cohort with > 20% staining for CD10.
CD10 immunohistochemistry of prostate cancer lymph node metastasisFigure 7
CD10 immunohistochemistry of prostate cancer 
lymph node metastasis. Positive staining is indicated by 
the brown chromogen deposit. Magnification is 40×.Page 10 of 11
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